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Purpose or Objective: Locally Advanced Non-Small Cell Lung 
Cancer (LA-NSCLC) or stage (St) III disease accounts for about 
30% of patients with NSCLCs. Treatment strategies include 
definitive chemoradiation or induction treatment (IT) 
followed by radical surgery. The main end-points of inductive 
treatment are resection rate with pneumonectomy rate, and 
pathological downstaging. 
 
Material and Methods: Pooled data from four consecutive 
trials published on patients receiving radiochemotherapy 
from 1992-2007 have been analyzed. The study group 
comprised 199 patients (87% males, 63±9 mean age, 48% 
squamous cell carcinoma (SCC), 65% cStIIIA). Patients have 
been treated with involved field radiotherapy and concurrent 
carboplatin or cisplatin + 5-FU (old drugs), weekly 
Gemcitabine only at 300mg/m2(GEM) and Cisplatin at 
systemic dose plus weekly Gemcitabine at 300mg/m2 (P-
GEM). 
 
Results: Present series confirms the impact on survival 
endpoints (OS, DFS, DSS) of surgical resection, pathological 
downstaging and tumor response. The indication for resection 
(HR = 2.7 [95%CI: 1.9; 3.7]; p<0.0001), together with 
response to radiochemotherapy (HR = 2.3 [95%CI: 1.6; 3.3]; 
p<0.0001) were the strongest predictors of OS. The most 
significant predictors of DSS were surgery (No resection vs 
Resection - HR: 2.0 [95%CI:1.3; 2.9], p<0.001), and the 
presence of response to induction radiochemotherapy (No 
response vs Partial Response - HR: 2.0 [95%CI:1.2; 3.1], 
p<0.004).Concurrent compounds influenced pathological 
downstaging (4% pStage 0 with old drugs vs. 23% with GEM vs. 
36% with P-GEM; p=0.01), response rate (79% and 80% of 
partial response with GEM and P-GEM vs. 68% with old drugs; 
p= 0.002) and pneumonectomy rate (33% of patients treated 
with old drugs, 29% of those treated with GEM, and 19% of 
those treated with P-GEM). Squamous histology influenced 
response rate (80% vs. 69%; p=0.009) and disease specific 
survival (median DSS time was 30 months vs. 20 months). 
 
Conclusion: The roles of major survival predictors 
(particularly, surgery, pathological downstaging) are 
discussed. The availability of reliable surrogate end-points 
(e.g.: pathological downstaging) may drive clinical strategy in 
the short time combining concurrent compounds and tumor 
histology. 
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Purpose or Objective: The aim of our study was to evaluate 
the efficacy and safety of brain stereotactic radiotherapy 
(BSRT), and potential interactions with mutational 
status/systemic therapies of patients treated in our Institute. 
 
Material and Methods: We conducted a retrospective study 
of 85 patients (150 lesions) receiving SRT for brain 
metastases (mets) of lung cancer between 01/2012 and 
03/2015. 
 
Results: 90% patients were smokers and the most frequent 
histology was adenocarcinoma (ADK: 74%). In 99 patients with 
mutational analysis: 35%, 8%, and 56% had EGFR/ALK, others 
(KRAS/PI3K), or no mutations, respectively. The median GPA-
DS score was 2.5 (0.5-3.5). The median estimated biologic 
equivalent dose (BED) was 57.6 Gy (16,7-57,6). 35 patients 
(41%) had a whole brain radiation therapy (WBRT) prior or 
after SABR. The median follow-up from SRT was 1.6 years. 
The 2-year local control (LC) was 54% (95IC: 40-68%). 
Histology (non-ADK: HR=7.2) and others mutations 
(KRAS/PI3K: HR=5.8) were associated with lower LC in the 
multivariate analysis (MVA). The type of systemic treatment, 
or its delay before BSRT, as well as other variables (history of 
WBRT, GPA, number of brain mets) did not correlate with LC 
in the MVA. 
 
Conclusion: In our study, K-Ras mutational status seemed to 
be associated with poorer local control. The impact of 
mutational status should be evaluated in a larger set of 
patients. 
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Purpose or Objective: Patients with recurrent lung cancer 
following prior thoracic radiation therapy have limited 
therapeutic options. This study analyzes the efficacy and 
morbidity associated with fractionated stereotactic body 
radiation therapy (SBRT) in the treatment of locally recurrent 
lung cancer following prior radiation therapy with or without 
concurrent chemotherapy or prior surgery. 
 
Material and Methods: 37 patients diagnosed with recurrent 
local lung cancer recurrence following prior thoracic 
radiation therapy were treated with stereotactic body 
radiation therapy between June 2009 and December of 2013 
at AtlantiCare Cancer Institute. Patients were treated with 
either robotic-assisted linear accelerator based stereotactic 
body radiation therapy with 4-D CT simulation and image 
guidance with cone beam CT or CyberKnife robotic 
radiosurgery utilizing Synchrony respiratory tracking. SBRT 
doses included 5400 cGy in 3 fractions and 5000 cGy in 5 
fractions depending on normal tissue dose constraints. 
Patients underwent routine imaging with PET/CT and CT for 
surveillance. 
 
Results: With a median follow-up of 3 years, the in-field local 
control was 92%. The actuarial overall survival was 46% with a 
progression free survival of 27%. Worsened dyspnea was 
noted in 13% of patients, 5% experienced esophagitis, 5% 
noted chest wall pain, and 8% experienced clinical 
pneumonitis. There was no grade 4 or 5 toxicity.  
 
Conclusion: For patients experiencing local recurrence 
following prior thoracic radiation, robotic SBRT offers both 
excellent local control and limited toxicity. Despite these 
favorable results, progressive failure outside of the local 
therapy field and competing co-morbidities continue to pose 
a significant challenge. 
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Purpose or Objective: Basing on the concept of 
oligometastases, i.e. less than 5 distant metastases, it was 
previously described that local, radical treatment of the 
